Vaccitech’s Immunotherapy Combo With Opdivo Shows Hepatitis B Promise

Searching For A Functional Cure

The UK company did not profit greatly from its role in COVID-19 vaccine, Vaxzevria, but hopes the same technology can form part of a breakthrough in hepatitis B.

ILC Congress 2022 London — Numerous new studies aiming for a functional cure in hepatitis B are being presented at the International Liver Congress in London. • Source: EASL

Shares in UK-based Vaccitech climbed by more than 40% after it reported encouraging early results from its ChAdOx1 vaccine platform used in a hepatitis B therapy, which looked strongest when combined with Bristol Myers Squibb’s immuno-oncology product Opdivo.

The news lifted the NASDAQ-listed company’s share price to $5.82 on 23 June, suggesting renewed belief in its next vaccine/immunotherapy...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Insmed Targets $5bn-Plus Market With Brinsupri For Bronchiectasis

13 Aug 2025

• By Mandy Jackson

The US FDA approved Insmed’s second product, the DPP1 inhibitor Brinsupri (brensocatib) for non-cystic fibrosis bronchiectasis. The company launched the drug immediately with a list price of $88,000 per year.

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

12 Aug 2025

• By Mary Jo Laffler

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

S&E In Brief: Launch Updates And Political Headwinds

12 Aug 2025

• By Sushmita Panda

Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.